Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.isci.2020.101585 http://scihub22266oqcxt.onion/10.1016/j.isci.2020.101585 32989429!7510433!32989429     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       iScience 2020 ; 23 (10): 101585 Nephropedia Template TP {{tp|p=32989429|t=2020. SARS-CoV-2 Infection Boosts MX1 Antiviral Effector in COVID-19 Patients |pdf=|usr=}}{{32989429}} gab.com Text SARS-CoV-2 Infection Boosts MX1 Antiviral Effector in COVID-19 Patients JO: iScience http://www.kidney.de/pget.php?&tw=1&pmid=32989429 #FOAvip In a published case-control study (GSE152075) from SARS-CoV-2-positive (n = 403) and -negative patients (n = 50), we analyzed the response to infection assessing gene expression of host cell receptors and antiviral proteins. The expression analysis associated with reported risk factors for COVID-19 was also assessed. SARS-CoV-2 cases had higher ACE2, but lower TMPRSS2, BSG/CD147, and CTSB expression compared with negative cases. COVID-19 patients' age negatively affected ACE2 expression. MX1 and MX2 were higher in COVID-19 patients. A negative trend for MX1 and MX2 was observed as patients' age increased. Principal-component analysis determined that ACE2, MX1, MX2, and BSG/CD147 expression was able to cluster non-COVID-19 and COVID-19 individuals. Multivariable regression showed that MX1 expression significantly increased for each unit of viral load increment. Altogether, these findings support differences in ACE2, MX1, MX2, and BSG/CD147 expression between COVID-19 and non-COVID-19 patients and point out to MX1 as a critical responder in SARS-CoV-2 infection. Twit Text FOAVip SARS-CoV-2 Infection Boosts MX1 Antiviral Effector in COVID-19 Patients ????iScience http://www.kidney.de/pget.php?&tw=1&pmid=32989429 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32989429 #FOAvip English Wikipedia <ref>{{Cite pmid|32989429}}</ref> SARS-CoV-2 Infection Boosts MX1 Antiviral Effector in COVID-19 Patients #MMPMID32989429 Bizzotto J; Sanchis P; Abbate M; Lage-Vickers S; Lavignolle R; Toro A; Olszevicki S; Sabater A; Cascardo F; Vazquez E; Cotignola J; Gueron G iScience 2020[Oct]; 23 (10): 101585 PMID32989429show ga In a published case-control study (GSE152075) from SARS-CoV-2-positive (n = 403) and -negative patients (n = 50), we analyzed the response to infection assessing gene expression of host cell receptors and antiviral proteins. The expression analysis associated with reported risk factors for COVID-19 was also assessed. SARS-CoV-2 cases had higher ACE2, but lower TMPRSS2, BSG/CD147, and CTSB expression compared with negative cases. COVID-19 patients' age negatively affected ACE2 expression. MX1 and MX2 were higher in COVID-19 patients. A negative trend for MX1 and MX2 was observed as patients' age increased. Principal-component analysis determined that ACE2, MX1, MX2, and BSG/CD147 expression was able to cluster non-COVID-19 and COVID-19 individuals. Multivariable regression showed that MX1 expression significantly increased for each unit of viral load increment. Altogether, these findings support differences in ACE2, MX1, MX2, and BSG/CD147 expression between COVID-19 and non-COVID-19 patients and point out to MX1 as a critical responder in SARS-CoV-2 infection. äSARS-CoV-2 Infection Boosts MX1 Antiviral Effector in COVID-19 Patient(epmc).pdf DeepDyve Pubget Overpricing